HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or…
News
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or…
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
Participating institutional investors include Bridgewest Group LOS ANGELES, June 14, 2023 (GLOBE NEWSWIRE) — Immix…
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
Participating institutional investors include Bridgewest Group LOS ANGELES, June 14, 2023 (GLOBE NEWSWIRE) — Immix…
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas…
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas…
EvolveImmune Therapeutics Enters into Strategic Research Collaboration with Kennedy Institute of Rheumatology
Collaboration with Researchers at University of Oxford to Utilize State-of-the-Art Technology to Characterize Immune Synapse…
EvolveImmune Therapeutics Enters into Strategic Research Collaboration with Kennedy Institute of Rheumatology
Collaboration with Researchers at University of Oxford to Utilize State-of-the-Art Technology to Characterize Immune Synapse…
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024…
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024…
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma…
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma…
Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
Tilray Brands Expands Beer Portfolio and Launches Good Supply Light Beer
Tilray Introduces New Easy-Drinking Light Beer Brand, Good Supply, in the U.S. Good Supply Easy…
Tilray Brands Expands Beer Portfolio and Launches Good Supply Light Beer
Tilray Introduces New Easy-Drinking Light Beer Brand, Good Supply, in the U.S. Good Supply Easy…
Jaden Smith to Speak at World’s Largest Psychedelic Science Conference
Multi-hyphenate entertainer, entrepreneur, advocate, and musician to speak about psychedelic medicine, healing, and mental health…
Jaden Smith to Speak at World’s Largest Psychedelic Science Conference
Multi-hyphenate entertainer, entrepreneur, advocate, and musician to speak about psychedelic medicine, healing, and mental health…
Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage…
Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage…